Effects of preoperative cisplatin and adriamycin chemotherapy for non-metastatic osteosarcoma / 대한내과학회지
Korean Journal of Medicine
;
: 59-65, 2003.
Article
in Korean
| WPRIM
| ID: wpr-211193
ABSTRACT
BACKGROUND:
Adjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. We studied the effectiveness of preoperative cisplatin and adriamycin combination chemotherapy in non-metastatic osteosarcoma.METHODS:
Twenty four cases of patient with osteosarcoma were divided into two groups except four patients treated only conservatively. Group A (14 patients) received chemotherapy before operation and Group B (6 patients) received chemotherapy after operation. The chemotherapy regimen consisted of cisplatin (120 mg/m2 on day 1) and adriamycin (adriamycin 25 mg/m2 on days 2 to 4).RESULTS:
The average age of the 20 patients was 27.5 years and the median follow-up duration was 39.3 months. 12 patients of group A were treated with limb-salvage operation and 2 patients with amputation because of tumor growing. According to Kaplan-Meier's plot, one year, three year overall survival rate were 100%, 85% in Group A and 100%, 75% in Group B. Histologic responses were assessed in patients received preoperative chemotherapy. Tumor necrosis over 90% is noted in 9 patients, under 90% necrosis is noted 5 patients. Their mean survival was 82 months and 25 months, respectively (p>0.05). CONCLSUION Adjuvant chemotherapy with cisplatin and adriamycin was feasible in non-metastatic osteosarcoma and clinically significant adverse effect was neutropenia.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Doxorubicin
/
Osteosarcoma
/
Survival Rate
/
Follow-Up Studies
/
Cisplatin
/
Chemotherapy, Adjuvant
/
Limb Salvage
/
Drug Therapy
/
Drug Therapy, Combination
/
Amputation, Surgical
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS